Tumor sample context
Tumor type, collection site, sample condition, expected timing and available ethics documentation.
HCC PDO / PDO 2.0
Use conventional PDOs for HCC efficacy studies. Immunotherapy or anti-angiogenic programs can add PDO 2.0, vascular-marker profiling or a purpose-built co-culture.
H&ECD31HEP-1
Model source
Patient HCC tissue
Culture / format
PDO · ALI · Immune co-culture study format
Available study data
TRiCBIO HCC PDO study data
Model characterization
HCC PDO culture and tissue-marker images
Bright-field and whole-mount fluorescence images show HCC PDO culture. H&E, CD31 and figure-labelled HEP-1 staining compare source tissue and PDO context.
View imageConventional PDO culture: bright-field and whole-mount immunofluorescence show model morphology and cell state, supporting characterization and downstream endpoint design.
Study data
View imageHCC tissue and model profiling: H&E histology and figure-labelled CD31 and HEP-1 immunohistochemistry in source tissue and PDO provide tissue-architecture and marker-staining context for subsequent target and mechanism studies.
Model & assay dataStudy planning
Models and assays for your study
Tumor type, sample condition, candidate and intended comparison guide the culture format, controls and assays.
Candidate and study objective
Modality, dosing plan, controls and the response or comparison the study should address.
Assays and deliverables
Planned histology, flow, molecular or functional assays, together with preferred data and report formats.
Study design
Interpret HCC drug response from tissue and model identity
HCC PDO studies combine source tissue, model identity, immune or vascular context and treatment response, connecting activity readouts with tissue biology to explain differences among candidates.
Confirm source and pathology
Review the documented liver-tumor pathology, sampling site, prior treatment and available pathology.
Compare tissue and model
Use H&E and hepatic, epithelial or endothelial markers to establish the model-identity baseline for efficacy studies.
Design treatment around mechanism
Set doses, time points and controls around small-molecule, ICB, anti-angiogenic or combination mechanisms.
Interpret response in context
Compare candidates using viability, histology, immune composition, cytokine or flow results in context.
Research applications
Recommended applications
- Candidates and combinations
- ICB and anti-angiogenic mechanism studies
- Tumor, immune and vascular-marker profiling
Assays & QC
Tumor identity, efficacy and immune readouts
Key markers
H&ECD31HEP-1
Available assays
- H&E / IF
- Flow cytometry
- Viability
- Cytokines
QC approach
Hepatic identity and tissue architecture establish the model baseline, followed by immune, vascular-marker and functional readouts matched to the selected system.
Study & delivery
Model characterization, treatment data and reporting
Choose a supplied model or a TRiCBIO-run efficacy and mechanism study. Typical deliverables include imaging, assay data, analysis and a study report.
Study design
Model establishment, tissue identity and functional readouts are analyzed with sample provenance, sample size and prespecified statistics.
Related solutions
Related study options
PROJECT DISCUSSION
Discuss a HCC PDO / PDO 2.0 study
Tell us about the tumor type, samples, candidate and results you want to compare. Our scientists will help plan your HCC PDO / PDO 2.0 study.